Scarica l'app Stockscreener
34.51
1.71%
0.58
Pre-mercato:
35.00
0.49
+1.42%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ROIV Giù?
Forum
Previsione
Precedente Chiudi:
$33.93
Aprire:
$33.75
Volume 24 ore:
3.83M
Relative Volume:
0.65
Capitalizzazione di mercato:
$24.82B
Reddito:
$8.26M
Utile/perdita netta:
$-397.91M
Rapporto P/E:
-68.53
EPS:
-0.5036
Flusso di cassa netto:
$-758.56M
1 W Prestazione:
-4.06%
1M Prestazione:
+10.61%
6M Prestazione:
+49.20%
1 anno Prestazione:
+196.22%
Intervallo 1D:
$33.56
$34.84
Intervallo di 1 settimana:
$33.56
$35.62
Portata 52W:
$10.90
$37.00
Roivant Sciences Ltd Stock (ROIV) Company Profile
Nome
Roivant Sciences Ltd
Settore
Industria
Telefono
441-295-5950
Indirizzo
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
34.51 | 24.40B | 8.26M | -397.91M | -758.56M | -0.5036 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-20 | Iniziato | Bernstein | Outperform |
| 2025-09-02 | Iniziato | Citigroup | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-01-05 | Iniziato | Piper Sandler | Overweight |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-17 | Iniziato | Guggenheim | Buy |
| 2023-06-08 | Iniziato | BofA Securities | Neutral |
| 2022-10-27 | Iniziato | JP Morgan | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Iniziato | Goldman | Buy |
| 2021-11-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-28 | Iniziato | Citigroup | Buy |
| 2021-10-26 | Iniziato | Cowen | Outperform |
| 2021-10-26 | Iniziato | Jefferies | Buy |
| 2021-10-26 | Iniziato | Truist | Buy |
Mostra tutto
Roivant Sciences Ltd Borsa (ROIV) Ultime notizie
Why is Billionaire Joe Edelman Bullish on Roivant Sciences (ROIV) - Kavout | AI
Pfizer, BioNTech face global patent suits from Arbutus, Roivant over COVID vaccine tech - Seeking Alpha
Roivant unit Genevant, Arbutus file patent infringement suits against Pfizer, BioNTech over LNP technology - Bitget
ROIV Stock Nears Record High –Retail Traders See Breakout After Surprise Earnings Beat - Stocktwits
Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring the 9.47% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
Roivant Sciences (ROIV) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Roivant’s Gline: From spin-cos to commercial conviction - biocentury.com
Roivant Sciences (ROIV) Climbs 2%: Biotech Stock Tests Key Resistance Near $38.65Moving Average Ribbon - dars.gov.et
Responsive Playbooks and the ROIV Inflection - Stock Traders Daily
Roivant Sciences (ROIV) Leerink Global Healthcare Conference 2026 Summary - Quartr
Roivant Sciences stock hits all-time high at 35.92 USD By Investing.com - Investing.com Nigeria
Roivant Sciences stock hits all-time high at 35.92 USD - Investing.com
Could Roivant Sciences Be a Multibagger Stock Over the Next 5 Years? - Yahoo Finance
Roivant Sciences Ltd. (ROIV) Stock Analysis: Potential Upside Amidst Biotech Innovations - DirectorsTalk Interviews
If You Invested $1,000 in Roivant Sciences (ROIV) - Stock Titan
ROIVRoivant Sciences Ltd Dividends - Finviz
Roivant Sciences Insider Sold Shares Worth $610,252, According to a Recent SEC Filing - Moomoo
Roivant Sciences (ROIV) director exercises options, sells 10,000 common shares - Stock Titan
Roivant Sciences (ROIV) Left Key Russell Indexes, Is It Still 10% Below Fair Value? - simplywall.st
Roivant Sciences (ROIV) director sells 17,750 shares after exercising options - Stock Titan
Roivant Sciences Insider Sold Shares Worth $56,444,076, According to a Recent SEC Filing - marketscreener.com
Roivant Sciences Insider Sold Shares Worth $49,354,076, According to a Recent SEC Filing - marketscreener.com
Roivant Sciences (ROIV) director-linked entity reports 1.44M-share open-market sale - Stock Titan
Form 144 ROIVANT SCIENCES LTD. For: 30 June - Investing.com UK
Roivant Sciences(ROIV.US) Director Sells US$56.44 Million in Common Stock - Moomoo
Roivant Sciences Director Sold Shares Worth Over $56M - TradingView
Form 144 ROIVANT SCIENCES LTD. For: 30 June By Investing.com - Investing.com Nigeria
Is Roivant Sciences (ROIV) Losing Its Defensive Status or Reframing Its Risk Narrative? - simplywall.st
Roivant Sciences Insider Sold Shares Worth $34,105,000, According to a Recent SEC Filing - Moomoo
Roivant Sciences Ltd.(NasdaqGS: ROIV) dropped from Russell 1000 Value-Defensive Index - marketscreener.com
Roivant Sciences Ltd.(NasdaqGS: ROIV) dropped from Russell 1000 Defensive Index - marketscreener.com
Roivant Sciences Ltd. (ROIV) Stock Analysis: A Biotech Powerhouse with 14.59% Potential Upside - DirectorsTalk Interviews
Roivant Sciences Insider Sold Shares Worth $6,631,268, According to a Recent SEC Filing - Moomoo
Understanding the Setup: (ROIV) and Scalable Risk - Stock Traders Daily
Price to sales forward of Roivant Sciences Ltd. – NASDAQ:ROIV - TradingView
Enterprise value to revenue forward of Roivant Sciences Ltd. – NASDAQ:ROIV - TradingView
Enterprise value to revenue forward of Roivant Sciences Ltd. – DUS:87S - TradingView
Enterprise value to EBITDA forward of Roivant Sciences Ltd. – DUS:87S - TradingView
Enterprise value to EBIT forward of Roivant Sciences Ltd. – NASDAQ:ROIV - TradingView
Form 144 ROIVANT SCIENCES LTD. For: 26 June - Investing.com UK
Form 144 ROIVANT SCIENCES LTD. For: 26 June By Investing.com - Investing.com Nigeria
Price to earnings forward of Roivant Sciences Ltd. – NASDAQ:ROIV - TradingView
Roivant Sciences(ROIV.US) Officer Sells US$6.63 Million in Common Stock - Moomoo
Roivant (NASDAQ: ROIV) president sells 200K shares, exercises 200K stock options - Stock Titan
Form 144 ROIVANT SCIENCES LTD. For: 25 June - Investing.com UK
Form 144 ROIVANT SCIENCES LTD. For: 25 June By Investing.com - Investing.com South Africa
Roivant Sciences Ltd (ROIV) Institutional Confidence - TradingKey
JNJ Stock Price and Chart — NYSE:JNJ - TradingView
Price to book forward of Roivant Sciences Ltd. – NASDAQ:ROIV - TradingView
Roivant Sciences Ltd Azioni (ROIV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Roivant Sciences Ltd Azioni (ROIV) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Fitzgerald Meghan | Director |
Jun 30 '26 |
Sale |
34.90 |
10,000 |
349,000 |
42,963 |
| Epperly Melissa B, | Director |
Jun 29 '26 |
Option Exercise |
4.46 |
17,750 |
79,165 |
34,224 |
| Epperly Melissa B, | Director |
Jun 29 '26 |
Sale |
34.38 |
17,750 |
610,252 |
16,474 |
| MANCHESTER KEITH S | Director |
Jun 29 '26 |
Sale |
34.55 |
800,000 |
27,642,000 |
13,701,546 |
| MANCHESTER KEITH S | Director |
Jun 26 '26 |
Sale |
34.00 |
625,783 |
21,275,309 |
14,501,546 |
| MANCHESTER KEITH S | Director |
Jun 30 '26 |
Sale |
35.45 |
200,000 |
7,090,000 |
1,748,403 |
| MANCHESTER KEITH S | Director |
Jun 30 '26 |
Sale |
35.28 |
12,380 |
436,766 |
13,689,166 |
| Gold Daniel Allen | Director |
Jun 29 '26 |
Sale |
34.55 |
800,000 |
27,642,000 |
13,701,546 |
| Gold Daniel Allen | Director |
Jun 26 '26 |
Sale |
34.00 |
625,783 |
21,275,309 |
14,501,546 |
| Gold Daniel Allen | Director |
Jun 30 '26 |
Sale |
35.28 |
12,380 |
436,766 |
13,689,166 |
2.11%
0.80%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):